The UK and US have secured a important bilateral deal that will ensure no levies on British drug shipments going into the American market.
Key Provisions of the Deal
As part of the deal, the UK has committed to boost expenditure on medicines through the National Health Service (NHS). This commitment secures that duties on these crucial products will remain at zero for a period of the next three years.
This agreement comes after recent threats to dramatically increase import taxes on branded drug imports, with increases discussed up to 100%.
"This deal between the United Kingdom reinforces the worldwide climate for innovative medicines and brings long-overdue fairness to American-British medicine commerce," an announcement noted.
Economic Importance
Pharmaceuticals represent one of the the United Kingdom's biggest exports to the America, which is clearly the largest destination for major British pharmaceutical firms.
Export figures reveal that in the year to the end of last September, the UK shipped drugs totaling billions to the US. This value accounted for nearly one-fifth of British export trade in that span.
"This agreement secures jobs, stimulates capital expenditure and facilitates the UK to establish itself as a global hub for medical research," a minister commented.
Specific British Pledges
The pact includes several specific pledges from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to raise total NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount manufacturers must pay back to the NHS to prevent overspending will be limited at 15%. Last year, rebates exceeded 20%.
Recent Tensions
This agreement comes amid a ongoing dispute between the sector and the UK government over drug pricing and NHS adoption.
This friction were heightened by assertions that American consumers were paying a premium for the identical medicines than people in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been halted or cancelled, while major funding commitments have been announced toward American operations.
One official publicly accepted that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had declined as a percentage of its resources over the previous ten-year period.
